Biocon Ltd is a biopharmaceutical company focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. It has four reportable segments: Generics, Biosimilars, Novel Biologics, and Research services. Its subsidiary, Syngene, provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies. Biocon Biologics Limited is a fully integrated global biosimilars organization with a strong research pipeline across various diseases. It has successfully taken six molecules from lab to market in developed markets and is committed to transforming healthcare and enabling affordable access to millions of patients worldwide.